NASDAQ:NEO - NeoGenomics Stock Price, Forecast & News

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

NeoGenomics, Inc. (NASDAQ:NEO) announced its earnings results on Tuesday, October, 29th. The medical research company reported $0.07 EPS for the quarter, beating analysts' consensus estimates of $0.06 by $0.01. The medical research company earned $104.70 million during the quarter, compared to the consensus estimate of $99.38 million. NeoGenomics had a return on equity of 4.60% and a net margin of 0.55%. The firm's revenue for the quarter was up 51.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.05 earnings per share. View NeoGenomics' Earnings History.

NeoGenomics is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for NeoGenomics.

6 brokerages have issued 12-month target prices for NeoGenomics' stock. Their forecasts range from $14.00 to $30.00. On average, they anticipate NeoGenomics' share price to reach $22.60 in the next twelve months. This suggests that the stock has a possible downside of 29.5%. View Analyst Price Targets for NeoGenomics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NeoGenomics.

News coverage about NEO stock has trended somewhat negative this week, according to InfoTrie. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. NeoGenomics earned a media sentiment score of -1.7 on InfoTrie's scale. They also gave media stories about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for NeoGenomics.

NeoGenomics saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 6,920,000 shares, an increase of 9.1% from the December 15th total of 6,340,000 shares. Based on an average daily trading volume, of 678,300 shares, the days-to-cover ratio is presently 10.2 days. Currently, 7.0% of the company's shares are sold short. View NeoGenomics' Current Options Chain.

Some companies that are related to NeoGenomics include Varian Medical Systems (VAR), DENTSPLY SIRONA (XRAY), Alnylam Pharmaceuticals (ALNY), Steris (STE), Universal Health Services (UHS), GALAPAGOS NV/S (GLPG), Fisher & Paykel Healthcare (FPH), Insulet (PODD), West Pharmaceutical Services (WST), EXACT Sciences (EXAS), Teva Pharmaceutical Industries (TEVA), Elanco Animal Health (ELAN), Bio-Rad Laboratories (BIO.B), Bio-Rad Laboratories (BIO) and Mylan (MYL).

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Alibaba Group (BABA), NVIDIA (NVDA), Marvell Technology Group (MRVL), Micron Technology (MU), Netflix (NFLX), Amarin (AMRN), Canopy Growth (CGC), CVS Health (CVS), Advanced Micro Devices (AMD) and Exelixis (EXEL).

NeoGenomics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Summit Creek Advisors LLC (0.35%), State of Alaska Department of Revenue (0.08%), Louisiana State Employees Retirement System (0.03%), HWG Holdings LP (0.01%), OLD National Bancorp IN (0.01%) and Sciencast Management LP (0.01%). Company insiders that own NeoGenomics stock include Electric Co General, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lynn A Tetrault, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven A Ross, Steven C Jones and William Bonello. View Institutional Ownership Trends for NeoGenomics.

NEO stock was sold by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System, Summit Creek Advisors LLC and State of Alaska Department of Revenue. Company insiders that have sold NeoGenomics company stock in the last year include George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven C Jones and William Bonello. View Insider Buying and Selling for NeoGenomics.

NEO stock was acquired by a variety of institutional investors in the last quarter, including HWG Holdings LP, OLD National Bancorp IN and Sciencast Management LP. View Insider Buying and Selling for NeoGenomics.

Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NEO stock can currently be purchased for approximately $32.05.

NeoGenomics has a market capitalization of $3.35 billion and generates $276.74 million in revenue each year. The medical research company earns $2.64 million in net income (profit) each year or $0.13 on an earnings per share basis. NeoGenomics employs 1,500 workers across the globe.View Additional Information About NeoGenomics.

The official website for NeoGenomics is http://www.neogenomics.com/.

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected]